CTRI/2024/03/064134尚未招募3 期
Effectiveness of biopsychosocial model in the treatment of low back pain - A randomized controlled trial - nil
Ms Vedhika J0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Subjects with LBP
- •2.Duration more than 7 days
排除标准
- •1 Known Inflammatory spinal pathology
- •2 Lumbar radiculopathy
- •3 Subjects who had spinal fracture or surgery
- •4 Have lumbar pain of traumatic origin
- •5 Have participated in a exercise program in the past three months
- •6 Have Neurological, Cognitive and psychological problems
- •7 If they are current or past smokers or tobacco chewers
研究者
相似试验
进行中（未招募）
1 期
A study to learn about the safety and efficacy of CTX001 (the study drug product) to treat beta-thalassemia and severe sickle cell disease in patientsTransfusion-dependent ß-thalassemia (TDT) and severe sickle cell disease (SCD)MedDRA version: 21.0Level: PTClassification code 10040641Term: Sickle cell anaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.1Level: LLTClassification code 10054660Term: Thalassemia betaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2021-006390-37-DEVertex Pharmaceuticals Incorporated26
招募中
1 期
A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects with Transfusion-Dependent ß-Thalassemia or Severe Sickle Cell DiseaseCTIS2024-514641-12-00Vertex Pharmaceuticals Inc.22
进行中（未招募）
3 期
A Phase III Study of ARS-1 Administration in Patients with Food AllegyJPRN-jRCT2031230143Kenya Morita15
进行中（未招募）
1 期
A study to evaluate the effects of Nexium in Children with Erosive Esophagitis (EE)Erosive EsophagitisMedDRA version: 20.1Level: LLTClassification code 10063657Term: Erosive esophagitisSystem Organ Class: 100000004856EUCTR2020-002515-21-ESAstraZeneca AB100
招募中
3 期
Endoscopic evidence of maintenance of healing with oral NEXIUM in patients 1 to 11 years old with erosive esophagitis.2023-505454-18-00Astrazeneca AB54